ITCI - Intra-Cellular Therapies Q3 2022 Earnings Preview

• Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open.
• The consensus EPS Estimate is -$0.84 (+11.6% Y/Y) and the consensus Revenue Estimate is $66M (+197.2% Y/Y).
• Over the last 1 year, ITCI has beaten EPS estimates 0% of the time and has beaten revenue estimates 100% of the time.
• Over the last 3 months, EPS estimates have seen 1 upward revision and 8 downward. Revenue estimates have seen 9 upward revisions and 2 downward.

For further details see: